Chapter 3 Market and Technology Background
- Hypertension
- Pathophysiology and Pathogenesis
- Classification
- Prevalence of Hypertension
- Antihypertensive Drugs
- Commonly Prescribed Antihypertensive Drugs
- Side Effects of Antihypertensive Drugs
- Contraindications of Major Antihypertensive Drugs
- Resistant Hypertension
Chapter 4 Market Dynamics
- Growth Drivers
- Increasing Prevalence of Hypertension
- Rising Geriatric Population and Government Assistance for Prescription Drugs
- Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension
- Improved Awareness of Hypertension: Earlier Diagnosis and Treatment
- Market Restraints
- Patent Expirations of Branded Drugs
- Drug Development Process: High Cost and Pricing Pressures
- Market Opportunities
- Patent Expiration: Growth Opportunities for Generic Players
- Unmet Needs in Low- and Middle-Income Countries
Chapter 5 Market Breakdown by Drug Class
- Global Antihypertensive Drug Market
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Market Size and Forecast
- Market Analysis
- Angiotensin II Receptor Blockers
- Market Size and Forecast
- Market Analysis
- Beta Blockers
- Market Size and Forecast
- Market Analysis
- Calcium Channel Blockers
- Market Size and Forecast
- Market Analysis
- Diuretics
- Market Size and Forecast
- Market Analysis
- Combination Drug
- Market Size and Forecast
- Market Analysis
- Others
- Market Size and Forecast
- Market Analysis
Chapter 6 Market Breakdown by Region
- Global Market for Antihypertensives by Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- South America
- Market Size and Forecast
- Market Analysis
- Middle East and Africa
- Market Size and Forecast
- Market Analysis
Chapter 7 Regulatory Environment
- Regulations in the U.S.
- New Drug Approvals
- The FDA Modernization Act of 1997
- Fast-Track Status
- Special Protocol Assessments
- Medicare
- Principles for Clinical Evaluation of New Antihypertensive Drugs
- Hypertension Guidelines in the U.S.
- Regulations in Europe
- Hypertension Guidelines in Europe
- Pricing and Reimbursement
- Regulations in Asia-Pacific
- Regulations in Japan
- Regulations in China
- Regulations in India
Chapter 8 Patent Analysis
- Patent Length and Market Exclusivity
Chapter 9 Pipeline Analysis
- Overview of the Drug Development Process
- Pipeline Analysis of Antihypertensive Drugs
- Antihypertensive Drugs in Phase I Clinical Trials
- Antihypertensive Drugs in Phase II Clinical Trials
- Antihypertensive Drugs in Phase III Clinical Trials
- Late-Stage Pipeline Drugs
Chapter 10 Competitive Landscape
- Global Company Share Analysis
- Mergers and Acquisitions
- Agreements, Collaborations, and Partnerships
- Impact of Generic Antihypertensives on the Market
Chapter 11 Company Profiles
- ALLERGAN PLC
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- ASTELLAS PHARMA INC.
- Company Overview
- Products Offered
- Developments and Strategies
- ARBOR PHARMACEUTICALS LLC
- Company Overview
- Products Offered
- ASTRAZENECA PLC
- Company Overview
- Business Performance
- AstraZeneca plc Business Segment Revenue
- AstraZeneca Plc Revenue by Region Segment
- Product Portfolio
- Developments and Strategies
- BAYER AG
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- BOEHRINGER INGELHEIM GMBH
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- DAIICHI SANKYO CO. LTD.
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- ELI LILLY AND CO.
- Company Overview
- Products Offered
- Developments and Strategies
- GILEAD SCIENCES INC.
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- GLAXOSMITHKLINE PLC
- Company Overview
- Products Offered
- Developments and Strategies
- HIKMA PHARMACEUTICALS PLC
- Company Overview
- Products Offered
- JOHNSON & JOHNSON
- Company Overview
- Business Performance
- Product Portfolio
- Developments and Strategies
- LUPIN LTD.
- Company Overview
- Product Portfolio
- MERCK & CO. INC.
- Company Overview
- Products Offered
- Developments and Strategies
- NOVARTIS AG
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- PFIZER INC.
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- SANOFI
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
- TAKEDA PHARMACEUTICAL CO. LTD.
- Company Overview
- Product Portfolio
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Company Overview
- Products Offered
- UNITED THERAPEUTICS CORP.
- Company Overview
- Business Performance
- Products Offered
- Developments and Strategies
List of Tables
Summary Table: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 1: Classification of Hypertension or Blood Pressure
Table 2: Global Prevalence of Hypertension with Population Aged 18 Years or Older, by Country, 2015
Table 3: Commonly Prescribed Antihypertensive Drugs
Table 4: Side Effects with Different Classes of Antihypertensive Drugs
Table 5: Contraindications of Major Antihypertensive Drugs
Table 6: Prevalence of High Blood Pressure, by Gender and Age Group, U.S., 2016
Table 7: Prevalence Rates of Obesity for Male and Female in Australia, 1995-2015
Table 8: Patent Expiration Dates for Antihypertensive Drugs, 2016-2018*
Table 9: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 10: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, Through 2023
Table 11: ACE Inhibitors Drug, Branded/Generic FDA Approval
Table 12: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, Through 2023
Table 13: Global Market for Beta Blocker Drugs, by Region, Through 2023
Table 14: Global Market for Calcium Channel Blocker Drugs, by Region, Through 2023
Table 15: Global Market for Diuretics Drugs, by Region, Through 2023
Table 16: Global Market for Combination Drugs, by Region, Through 2023
Table 17: Commonly Prescribed Combinations of Antihypertensive Drugs
Table 18: Global Market for Other Antihypertensive Drugs, by Region, Through 2023
Table 19: Commonly Prescribed Types of Other Antihypertensive Drugs
Table 20: Global Market for Antihypertensive Drugs, by Region, Through 2023
Table 21: North American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 22: North American Market for Antihypertensive Drugs, by Country, Through 2023
Table 23: Total Number of High Blood Pressure Patients in Canada, by Age Group, 2016 and 2017
Table 24: European Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 25: European Market for Antihypertensive Drugs, by Country, Through 2023
Table 26: Asia-Pacific Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 27: Asia-Pacific Market for Antihypertensive Drugs, by Country, Through 2023
Table 28: South American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 29: Middle Eastern and African Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 30: Arbor Pharmaceuticals LLC: Antihypertensives Patent Exclusivity
Table 31: Allergan Plc: Antihypertensives Patent Exclusivity
Table 32: Chiesi USA Inc.: Antihypertensives Patent Exclusivity
Table 33: Eli Lilly and Co.: Antihypertensives Patent Exclusivity
Table 34: Gilead Sciences Inc.: Antihypertensives Patent Exclusivity
Table 35: GlaxoSmithKline plc: Antihypertensives Patent Exclusivity
Table 36: Novartis AG: Antihypertensives Patent Exclusivity
Table 37: Noden Pharma DAC: Antihypertensives Patent Exclusivity
Table 38: Johnson & Johnson: Antihypertensives Patent Exclusivity
Table 39: United Therapeutics Corp.: Antihypertensives Patents Exclusivity
Table 40: Other Applicants: Antihypertensives Patent Exclusivity
Table 41: Exclusivity Expiration of Antihypertensive Drugs
Table 42: Preclinical & Phase I Pipeline of Antihypertensive Drugs
Table 43: Phase II Pipeline of Antihypertensive Drugs
Table 44: Phase III Pipeline of Antihypertensive Drugs
Table 45: Generic Launches in the Antihypertensive Market, 2015-2018
Table 46: Allergan Plc: Antihypertensive Drugs Product Portfolio
Table 47: Astellas Pharma Inc.: Antihypertensive Drugs Product Portfolio
Table 48: Arbor Pharmaceutical LLC.: Antihypertensive Drugs Product Portfolio
Table 49: AstraZeneca Plc: Antihypertensive Drugs Product Portfolio
Table 50: Bayer AG: Antihypertensive Drugs Product Portfolio
Table 51: Boehringer Ingelheim GmbH: Antihypertensive Drugs Product Portfolio
Table 52: Daiichi Sankyo Co. Ltd.: Antihypertensive Drugs Product Portfolio
Table 53: Eli Lilly and Co.: Antihypertensive Drugs Product Portfolio
Table 54: Gilead Science Inc.: Antihypertensive Drugs Product Portfolio
Table 55: GlaxoSmithKline Plc: Antihypertensive Drugs Product Portfolio
Table 56: Hikma Pharmaceuticals Plc: Antihypertensive Drugs Product Portfolio
Table 57: Johnson & Johnson: Antihypertensive Drugs Product Portfolio
Table 58: Lupin Ltd.: Antihypertensive Drugs Product Portfolio
Table 59: Merck & Co. Inc.: Antihypertensive Drugs Product Portfolio
Table 60: Novartis AG: Antihypertensive Drugs Product Portfolio
Table 61: Pfizer Inc.: Antihypertensive Drugs Product Portfolio
Table 62: Sanofi: Antihypertensive Drugs Product Portfolio
Table 63: Takeda Pharmaceutical.: Antihypertensive Drugs Product Portfolio
Table 64: Teva Pharmaceutical Industries Ltd.: Antihypertensive Drugs Product Portfolio
Table 65: United Therapeutics Corp.: Antihypertensive Drugs Product Portfolio
Table 66: Acronyms Used in This Report
List of Figures
Summary Figure: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 1: Prevalence of Hypertension Among U.S. Adults Aged 18 and Older, by Sex and Age, 2016
Figure 2: Prevalence Rates for Adult Obesity, by Country, 2016
Figure 3: Diovan/Co-Diovan Revenue, 2013-2017
Figure 4: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 5: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, 2017-2023
Figure 6: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, 2017-2023
Figure 7: Global Market for Angiotensin II Receptor Blockers (ARBs), 2017-2023
Figure 8: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, 2017-2023
Figure 9: Leading ARBs Drug Prescriptions in the U.S., 2016
Figure 10: Global Market for Beta Blocker Drugs, 2017-2023
Figure 11: Global Market for Beta Blocker Drugs, by Region, 2017-2023
Figure 12: Global Market for Calcium Channel Blocker Drugs, 2017-2023
Figure 13: Global Market for Calcium Channel Blocker Drugs, by Region, 2017-2023
Figure 14: Global Market for Diuretics Drugs, 2017-2023
Figure 15: Global Market for Diuretics Drugs, by Region, 2017-2023
Figure 16: Global Market for Combination Drugs, 2017-2023
Figure 17: Global Market for Combination Drugs, by Region, 2017-2023
Figure 18: Global Market for Other Antihypertensive Drugs, 2017-2023
Figure 19: Global Market for Other Antihypertensive Drugs, by Region, 2017-2023
Figure 20: Global Market Share for Antihypertensive Drugs, by Region, 2017
Figure 21: North American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 22: North American Market Share for Antihypertensive Drugs, by Country, 2017
Figure 23: U.S. Market for Antihypertensive Drugs, 2017-2023
Figure 24: Canadian Market for Antihypertensive Drugs, 2017-2023
Figure 25: Mexican Market for Antihypertensive Drugs, 2017-2023
Figure 26: European Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 27: European Market Share for Antihypertensive Drugs, by Country, 2017
Figure 28: German Market for Antihypertensive Drugs, 2017-2023
Figure 29: French Market for Antihypertensive Drugs, 2017-2023
Figure 30: U.K. Market for Antihypertensive Drugs, 2017-2023
Figure 31: Italian Market for Antihypertensive Drugs, 2017-2023
Figure 32: Spanish Market for Antihypertensive Drugs, 2017-2023
Figure 33: Rest of Europe Market for Antihypertensive Drugs, 2017-2023
Figure 34: Asia-Pacific Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 35: Asia-Pacific Market Share for Antihypertensive Drugs, by Country, 2017
Figure 36: Japanese Market for Antihypertensive Drugs, 2017-2023
Figure 37: Chinese Market for Antihypertensive Drugs, 2017-2023
Figure 38: Indian Market for Antihypertensive Drugs, 2017-2023
Figure 39: Rest of Asia-Pacific Market for Antihypertensive Drugs, 2017-2023
Figure 40: South American Market for Antihypertensive Drugs, 2017-2023
Figure 41: South American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 42: Middle Eastern and African Market for Antihypertensive Drugs, 2017-2023
Figure 43: Middle East and African Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 44: China CFDA Drug Regulatory Approval Process
Figure 45: Global Antihypertensive Drug Market Share, by Manufacturer, 2017
Figure 46: Novartis AG: Sales Revenue for Co-Diovan/Diovan HCT, 2014-2017
Figure 47: Allergan Plc: Annual Revenue, 2013-2017
Figure 48: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 49: AstraZeneca Plc: Annual Revenue, 2013-2017
Figure 50: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 51: AstraZeneca Plc: Revenue Share, by Region, 2017
Figure 52: Bayer AG: Annual Revenue, 2013-2017
Figure 53: Bayer AG: Revenue Share, by Region, 2017
Figure 54: Boehringer Ingelheim GmbH: Annual Revenue, 2013-2017
Figure 55: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 56: Daiichi Sankyo Co. Ltd.: Annual Revenue, 2015-2017
Figure 57: Gilead Sciences Inc.: Annual Revenue, 2014-2017
Figure 58: Johnson & Johnson: Annual Revenue, 2013-2017
Figure 59: Johnson & Johnson: Revenue Share, by Region, 2017
Figure 60: Johnson & Johnson: Revenue Share, by Business Unit, 2017
Figure 61: Novartis AG.: Annual Revenue, 2013-2017
Figure 62: Novartis AG: Revenue Share, by Region, 2017
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2017
Figure 64: Pfizer Inc.: Annual Revenue, 2013-2017
Figure 65: Pfizer Inc.: Revenue Share, by Region, 2017
Figure 66: Pfizer Inc.: Revenue Share, by Business Segment, 2017
Figure 67: Sanofi.: Annual Revenue, 2013-2017
Figure 68: Sanofi: Revenue Share, by Region, 2017
Figure 69: United Therapeutics Corp: Annual Revenue, 2015-2017
